InspireMD (NSPR) Investor Presentation - Slideshow

Market Opportunity & Impact - Stroke is a major global health issue, causing 62 million deaths annually[10] and costing $34 billion annually in the US alone[10] - Carotid artery disease (CAD) is responsible for approximately 20% of ischemic strokes, affecting 22 to 24 million people[10] - The addressable market for stroke prevention devices is estimated to be over $1 billion[7, 31, 69] CGuard™ EPS Technology & Clinical Data - InspireMD's CGuard™ EPS, with its MicroNet™ technology, aims to shift the paradigm in carotid artery stenting (CAS) for stroke prevention[5, 7] - Clinical trials demonstrate the benefits of CGuard™ EPS, showing no device-related major adverse events and sustainable long-term results[7] - The MicroNet™ technology in CGuard™ EPS permanently covers plaque, preventing debris from passing through and acting as a "safety net"[5, 34, 38] - In the CARENET clinical trial, CGuard™ EPS showed zero major adverse cardiac or cerebral events (MACCE) at 30 days, compared to a comparative data of 572%[42] - PARADIGM 101 trial showed 991% device success, with 0% major stroke at 30 days[43] Commercial Growth & Strategy - CGuard™ EPS sales increased 55% year-over-year in 2018[7] - The company is evaluating opportunities to go direct in key markets and expanding into OUS markets like Brazil, Japan, and China[7] - The company submitted an IDE FDA submission for CGuard™ EPS in July 2019[7, 65] - The company's strategy includes transitioning current carotid stent users to CGuard™ EPS and vascular surgeons to CGuard™[61] Financials - As of October 31, 2019, the stock price was $113, with an average daily trading volume of 242K shares[75] - As of September 30, 2019, the company had $72 million in cash[75]